| Non-Alcoholic Fatty Liver Disease |
1 |
1 |
| Liver Biopsy |
0 |
0.86 |
| Liver |
0 |
0.8 |
| Aminotransferase |
0 |
0.75 |
| Biliary Disease |
0 |
0.74 |
| Fatty Liver |
0 |
0.62 |
| Liver Disease |
0 |
0.62 |
| Hepatic Fibrosis |
0 |
0.6 |
| Metabolic Syndrome |
0 |
0.54 |
| Biopsy |
0 |
0.42 |
| Lipids Management |
0 |
0.16 |
| Cardiovascular Risk Management |
0 |
0.12 |
| LDL Cholesterol |
0 |
0.12 |
| Type 2 Diabetes Mellitus |
0 |
0.12 |
| GLP-1 Receptor Agonist |
0 |
0.1 |
| Biomarker |
0 |
0.08 |
| Board Certification |
0 |
0.08 |
| Clinical Research |
0 |
0.08 |
| Europe |
0 |
0.08 |
| Healthcare and Medical Technology |
0 |
0.08 |
| Metabolism |
0 |
0.08 |
| Receptors |
0 |
0.08 |
| Spleen |
0 |
0.08 |